$JUNS News

Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value

Jupiter Neurosciences Doses First Participant In Its Phase 2a RESET Clinical Study Of JOTROL To Treat Parkinson's Disease

Jupiter Neurosciences Commences ~$2M Offering Of 307,692 Common Shares

Jupiter Neurosciences Enters Definitive License Agreement With PharmAla For Its Patented, Non-Racemic MDMA Formulation ALA-002

Jupiter Neurosciences, Inc. Announces Reverse Stock Split

Jupiter Neurosciences Announces 1-For-75 Reverse Stock Split, Effective Aug. 6

Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS)

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002

Jupiter Neurosciences Enters License Agreement With PharmAla Biotech For Perpetual Exclusive U.S. Rights To ALA-002; Deal Worth Up To $100M With Milestone Payments

Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson

Jupiter Neurosciences Registers Resale Of Up To 16M Shares By Selling Stockholders

Jupiter Neurosciences Initiates Patient Enrollment In Its Phase 2a RESET Clinical Study For JOTROL In Parkinson's Disease

D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering

Jupiter Neurosciences Files Prospectus For Offering 7.143M Common Shares

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for ALA-002 MDMA Therapy (MDXXF)

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal